Cell-free DNA Quality and Quantity Assessment – A Method Comparison 1Andrea Ullius, 2Elisa Viering, 2Eva Graf, and 1Thorsten Voss1PreAnalytiX GmbH, Hombrechtikon, Switzerland; 2Agilent Technologies, Waldbronn, Germany
IntroductionWorkflow standardization is required for successful use of circulating cell-free DNA (ccfDNA) in cancer research. The European technical specification for isolation of ccfDNA (CEN/TS 16835-3:2015) and future ISO standard focuses on preanalytical factors like preventing cellular DNA release by using blood stabilization tubes and dedicated isolation procedures. Furthermore, accurate determination of ccfDNA quality and quantity is required for downstream analyses like NGS, quantitative or digital PCR (qPCR/dPCR).
This research study compares common methods for quality control of ccfDNA from venous whole blood collected and stored for 7 days in EDTA and PAXgene® Blood ccfDNA Tubes* and processed with manual and automated preparation kits.
MethodsBlood from eight healthy donors was collected in EDTA (BD) and PAXgene Blood ccfDNA Tubes† (PreAnalytiX). Paired tubes were processed directly (T0) or after storage for 7 days (T7d) at 25°C. CcfDNA extraction was performed manually using the QIAamp Circulating Nucleic Acid Kit (QA, QIAGEN) or automated on the QIAsymphony® instrument (QS) using tube-specific kits and protocols. All 64 samples were analyzed for ccfDNA quality and/or quantity with QC methods based on fluorescence, automated electrophoresis and PCR according to Table 1.
Method category Assay Name Instrument Supplier
Fluorometric measurement
QubitTM dsDNA HS Assay Kit (10x)*
Qubit 2.0 Thermo Fisher ScientificQubit 1x dsDNA HS
Assay Kit* - premixed kit
Automated electrophoresis
Cell-free DNA ScreenTape assay*
4200 TapeStation System Agilent Technologies
qPCRInvestigator®
Quantiplex Pro†
(91 bp amplicon)Rotor-Gene® Q QIAGEN
dPCR18S rDNA 66 bp
(QIAGEN in-house assay)QX200TM Droplet
Digital PCRTM System(QIAGEN)/BioRad
Table 1 - Methods used for ccfDNA quality and quantity assessment
ResultsTotal ccfDNA quantification
• Manual and automated ccfDNA extraction methods enable high workflow consistency and comparable ccfDNA yields quantified with the TapeStation system, Qubit 1x, Quantiplex Pro and 18S ddPCR assays
• Storage of unstabilized blood in EDTA tubes for 7 days at 25°C results in up to 80-fold increase of total DNA in plasma Stabilization for consistent ccfDNA quantification is needed
• Electrophoretic and PCR-based DNA quantification methods show comparable results when analyzing low and high ccfDNA concentrations
• Fluorometric assays (Qubit 1x and 10x) show higher variation when measuring ccfDNA. For high concentration ranges both Qubit assays have limited measuring capacity
TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR
150
100
50
0
ng D
NA
/elu
ate
PAXgene T0 QS (automated)
EDTA T0 QS (automated)PAXgene T0 QA (manual)
EDTA T0 QA (manual)A
Four of five investigated quantification assays resulted in comparable yield quantification
Yield of total ccfDNAManual/automated extraction methods
TapeStation Qubit 10x Qubit 1x Quantiplex Pro 18S ddPCR
5000040000300002000010000
50004000300020001000
0
pg D
NA
/μl e
luat
e
B
ccfDNA from blood stored for 7 days in PAXgene tubes shows no significant difference in concentration, while ccfDNA concentration from blood stored in EDTA tubes is highly elevated.
Concentration of total ccfDNAStored whole blood
PAXgene T7d
EDTA T7dPAXgene T0
EDTA T0
Comparison of quantification methods for ccfDNA samples of plasma from stored and unstored whole venous blood collected in EDTA and PAXgene Blood ccfDNA Tubes. (A) Total DNA yield quantification (ng DNA/eluate) of ccfDNA eluates isolated with QIAamp (QA) and QIAsymphony (QS) from unstored EDTA and PAXgene samples (T0), n = 8. (B) Concentration of total ccfDNA (pg DNA/µl eluate) extracted from plasma of unstored (T0) and stored (T7d) EDTA and PAXgene samples using QIAamp, n = 8. Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method). Outliers are shown as dots, extremes were excluded from analysis.
ccfDNA qualification and quantification
• PAXgene Blood ccfDNA stabilization ensures reliable and consistent ccfDNA quantification and qualification of unstored and stored blood samples
• Blood storage in EDTA tubes leads to gDNA release resulting in an increase of high molecular weight (HMW) DNA and ccfDNA (degraded gDNA) concentration
• The new Cell-free DNA ScreenTape assay enables total quantification as well as quantification of a predefined cfDNA region (from 50 to 700 bp) without an upper marker
25000
8000
7000
6000
5000
4000
Sam
ple
Inte
nsity
[Nor
mal
ized
FU
] p
g D
NA
/μl e
luat
e
Size
(bp)
3000
2000
1000
0
35 50 75 100
150
200
300
400
500
600
700
1000
Size[bp]
Size[bp]
200
190
180
170
160
200001500010000
5000
1500
1000
500
0
Lower marker
Lower marker
Detail
cfDNA region (50–700 bp) HMW DNA
DNA concentration of cfDNA region(preset region: 50–700 bp)
Mononucleosome peak
A B
HMW DNA
C
T0
EDTA
cfDNA region (50–700 bp)
Mononucleosome peak
D
T0 T7dT7d
PAXgene
T0
EDTA
T0 T7dT7d
PAXgene
Fragment size mononucleosome peak(in bp)
PAXgene T7dEDTA T7d PAXgene T0EDTA T0
500
400
300
200
100
0
35 50 75 100
150
200
300
400
500
600
700
1000
ccfDNA qualification and region quantfication on the TapeStation system (TS) using the Cell-free DNA ScreenTape assay
(A) Overlay of ccfDNA electropherogram profiles from one exemplary donor. Quantification of ccfDNA is evaluated by the assay using a pre-set region from 50–700 bp. Indicated are the lower marker, mononucleosomal peak and HMW DNA. (B) Detail of indicated region from figure A. (C) ccfDNA concentration in the pre-set region of 50–700 bp (in pg DNA/µl eluate), n = 8. (D) Main peak size of mononucleosomal peak (in bp) as evaluated by the TapeStation Analysis software (n = 8). Data presented as box plots with median and upper and lower quartiles, whiskers with maximum 1.5 interquartile ranges (Tukey method).
Study Design
Conclusions• The PAXgene Blood ccfDNA workflow using manual or automated ccfDNA extraction is compatible with quantification
instruments including Qubit and TapeStation as well as PCR-based methods resulting in comparable yield quantification across different methods
• The yield of smaller ccfDNA fragments (50–700 bp) and ccfDNA fragment size is consistent in plasma from blood stored for 7 days in PAXgene Blood ccfDNA Tubes and comparable to EDTA T0 (control). It can be analyzed with the new Cell-free DNA ScreenTape assay
• The release of genomic DNA in EDTA tubes (as HMW and cell-free DNA) over time indicates the need for stabilization of blood in PAXgene Blood ccfDNA Tubes and an accurate quantification method for optimal workflow control
Disclaimer *For Research Use Only. Not for use in diagnostic procedures.†For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN or PreAnalytiX kit handbook or user manual. QIAGEN and PreAnalytiX kit handbooks and user manuals are available at www.qiagen.com or www.preanalytix.com or can be requested from QIAGEN Technical Services or your local distributor.
Trademarks are the property of their respective owners.
© 2019 PreAnalytiX GmbH. PreAnalytiX, the PreAnalytiX Logo and all other trademarks are property of PreAnalytiX GmbH, Hombrechtikon, CH.
ccfDNA QC workflow
Bloodcollection
Samplestorage
+plasma
separation
ccfDNAextraction
SampleQC
PAXgene Blood ccfDNA Tube
Qubit 2.0
Rotor-Gene Q
Droplet Digital PCR
Quantification + Qualification
RFU50004000300020001000
00 10 20 30 40
Cycles
4200 TapeStation SystemQIAsymphony instrument
QIAamp Circulating Nucleic Acid Kit
BD Vacutainer® K2EDTA Tube